|
Ka (hr-1)
|
Absorption rate constant
|
0.032 (0.029-0.034)
|
29% (18) (30)
| |
|
Vc/F (liters)
|
Central volume
|
25.6 (16.21-34.99)
|
82% (24) (51)
| |
|
CL/F (liters/hr)
|
Clearance
|
4.54 (3.913-5.167)
|
0*
|
19% (22) (44)
|
|
Q/F (liters/hr)
|
Inter-compartmental exchange Clearance
|
1.23 (0.99-1.47)
|
27% (24) (23)
| |
|
Vp/F (liters)
|
Peripheral Volume
|
203 (167.13-238.87)
|
39% (22) (37)
| |
|
t lag (hr)
|
Absorption lag time
|
1.45 (1.25-1.65 )
|
0*
| |
|
F1
|
Bioavailability (population typical value)
|
1*
|
47% (11) (5)
| |
|
F1 EFV
|
Relative bioavailability for patients on Efavirenz
|
0.42 (0.34-0.5)
| | |
|
F1 NEV
|
Relative bioavailability for patients on Nevirapine
|
1.32 (1.08-1.52)
| | |
|
ADD
|
Additive residual error
|
26.30 (4.15-48.44)
| | |
|
PROP
|
Proportion residual error
|
0.083 (0.06-0.10)
| | |
